tiprankstipranks
Trending News
More News >
Financiere de Tubize SA (DE:FTD)
FRANKFURT:FTD
Advertisement

Financiere de Tubize (FTD) Price & Analysis

Compare
5 Followers

FTD Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

1.25%96.93%
Insiders
1.25%
Mutual Funds
― Other Institutional Investors
96.93% Public Companies and
Individual Investors

FTD FAQ

What was Financiere de Tubize SA’s price range in the past 12 months?
Financiere de Tubize SA lowest stock price was €106.60 and its highest was €154.20 in the past 12 months.
    What is Financiere de Tubize SA’s market cap?
    Financiere de Tubize SA’s market cap is €6.38B.
      When is Financiere de Tubize SA’s upcoming earnings report date?
      Financiere de Tubize SA’s upcoming earnings report date is Aug 02, 2025 which is in 7 days.
        How were Financiere de Tubize SA’s earnings last quarter?
        Currently, no data Available
        Is Financiere de Tubize SA overvalued?
        According to Wall Street analysts Financiere de Tubize SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Financiere de Tubize SA pay dividends?
          Financiere de Tubize SA pays a Annually dividend of €0.727 which represents an annual dividend yield of 0.59%. See more information on Financiere de Tubize SA dividends here
            What is Financiere de Tubize SA’s EPS estimate?
            Financiere de Tubize SA’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Financiere de Tubize SA have?
            Financiere de Tubize SA has 44,512,600 shares outstanding.
              What happened to Financiere de Tubize SA’s price movement after its last earnings report?
              Currently, no data Available
              Which hedge fund is a major shareholder of Financiere de Tubize SA?
              Currently, no hedge funds are holding shares in DE:FTD

              Company Description

              Financiere de Tubize SA

              Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.
              Similar Stocks
              Company
              Price & Change
              Follow
              Financiere de Tubize
              Financiere de Tubize
              Legal & General
              Popular Stocks
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis